Polidocanol (Polyoxyethylene lauryl ether)
(Synonyms: 聚多卡醇; Polyoxyethylene lauryl ether; Polyoxyethyleneglycol Dodecyl Ether) 目录号 : GC32477
Polidocanol (Polyoxyethylene lauryl ether, Polyoxyethyleneglycol Dodecyl Ether, Brij30, Laureth-23, Varithena) is a sclerosant used for treating uncomplicated spider veins and reticular veins in the lower extremities.
Cas No.:9002-92-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Polidocanol (Polyoxyethylene lauryl ether, Polyoxyethyleneglycol Dodecyl Ether, Brij30, Laureth-23, Varithena) is a sclerosant used for treating uncomplicated spider veins and reticular veins in the lower extremities.
[1] Margaret Mann, et al. J Drugs Dermatol. 2019 Nov 1;18(11):1124-1127.
| Cas No. | 9002-92-0 | SDF | |
| 别名 | 聚多卡醇; Polyoxyethylene lauryl ether; Polyoxyethyleneglycol Dodecyl Ether | ||
| Canonical SMILES | OCCCOCCCCCCCCCCCCC.[n] | ||
| 分子式 | (C2H4O)nC12H26O | 分子量 | |
| 溶解度 | Water : 50 mg/mL ;DMSO : 50 mg/mL | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Polidocanol Sclerotherapy in Pyogenic Granulomas
Dermatol Surg 2022 Jan 1;48(1):72-75.PMID:34816819DOI:10.1097/DSS.0000000000003308.
Background: Polidocanol is a safe sclerosing agent with anesthetic properties and minimal skin toxicity. Objective: To evaluate the efficacy, safety, and recurrence rates with Polidocanol sclerotherapy in the treatment of pyogenic granulomas (PGs). Methods and methods: Thirty-nine patients with PG were injected with Polidocanol 1% solution. Repeat injections were given weekly in case of incomplete clinical/dermoscopic resolution, until a maximum of 3 sittings. A higher strength (3%) was used for subsequent sessions in those with a minimal response to 1% solution. A final assessment for relapses was performed at 3, 6, and 12 months. Results: All 39 patients achieved complete resolution (100% clearance rate), with most (n = 26) lesions resolving after the first sitting. Side effects noted were postprocedure pain (22), erythema (2), superficial ulceration (2), paresthesias (1), prominent edema (4), thrombophlebitis (1), cyanotic discoloration (1), purpuric staining around injection site (4), and mild local pruritus (1). The procedure was well tolerated across the age spectrum (4-63 years) included. Conclusion: We report Polidocanol to be a highly effective, safe, and cost-effective sclerosant for treatment of PGs with no recurrences or need for special postprocedure care.
Skin hyperpigmentation after sclerotherapy with Polidocanol: A systematic review
J Eur Acad Dermatol Venereol 2023 Feb;37(2):274-283.PMID:36196455DOI:10.1111/jdv.18639.
Skin hyperpigmentation after sclerotherapy with polidocanol-containing sclerosants is a common local side effect. Sclerotherapists should be familiar with factors that trigger hyperpigmentation after sclerotherapy with polidocanol-containing sclerosants. A systematic literature review of works reporting hyperpigmentation after sclerotherapy for telangiectasias, reticular veins, side branches and truncal varices with polidocanol-containing sclerosants was performed. Reported incidence rates, follow-up periods and potentially triggering factors were assessed and analysed. The search yielded 1687 results; of these, 27 reports met the inclusion criteria. The incidence of hyperpigmentation seemed to increase with higher concentrations of Polidocanol and was more evident after sclerotherapy for epifascial veins than for intrafascial truncal veins when the Polidocanol concentration was more than 0.25%. Regarding sclerotherapy for telangiectasias and reticular veins, the incidence of hyperpigmentation ranged between 2% and 25% for Polidocanol 0.25% (liquid and foam), between 12.5% and 67.9% for Polidocanol 0.5% (liquid and foam) and between 13% and 73% for Polidocanol 1% (liquid and foam). Regarding truncal veins, the incidence ranged from 7% to 45.8% for Polidocanol 1% (liquid and foam), from 16% to 17% for Polidocanol 2% (foam) and from 7.4% to 32.5% for Polidocanol 3% (liquid and foam). Regarding the treatment of side branches, the incidence of hyperpigmentation ranged from 5.6% to 53% for both foam and liquid sclerotherapy. Regarding the duration of hyperpigmentation, there are few data describing reticular veins and telangiectasias. Hyperpigmentation persisting for more than 6 months has been reported to have an incidence of up to 7.5%. Hyperpigmentation persisting for more than 1 year after foam Polidocanol 1%-3% treatment for truncal veins has an incidence ranging from 8.1% to 17.5%. Other factors such as higher volumes and compression therapy after treatment seem to have a minor influence. Data regarding hyperpigmentation after polidocanol-related sclerotherapy are poor and should be improved by higher-quality research.
Polidocanol: A Review of Off-Label Dermatologic Uses
Dermatol Surg 2022 Sep 1;48(9):961-966.PMID:36054050DOI:10.1097/DSS.0000000000003520.
Background: Polidocanol is an FDA-approved treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, but numerous other off-label dermatological applications have been reported. Objective: To describe the various off-label dermatological clinical uses of Polidocanol, as well as efficacy and adverse effects. Methods: The review of studies searchable on PubMed from 2004 to 2021 describing clinical uses of Polidocanol to determine efficacy and adverse effects associated with various dermatologic applications. Results: Polidocanol has shown efficacy in the treatment of mucocele of minor salivary gland, hemangioma, upper extremity veins, reticular veins of the chest, facial veins, pyogenic granuloma, lymphangioma circumscriptum, digital mucous cyst, mixed skin ulcers, cutaneous focal mucinosis, seromas, glomuvenous malformations, acne cysts, lymphocele, and dissecting cellulitis. Commonly reported side effects include pain, erythema, swelling, ecchymosis, and ulceration. Most sources were case reports and small prospective studies, as such the strength of data supporting many uses is limited by small sample sizes and lack of controls. Conclusion: Although Polidocanol is currently only FDA approved for incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, the use of Polidocanol has been selected for a variety of off-label clinical applications.
Solubilization of membrane-bound matrix-induced alkaline phosphatase with polyoxyethylene 9-lauryl ether (Polidocanol): purification and metalloenzyme properties
Int J Biochem 1990;22(4):385-92.PMID:2159926DOI:10.1016/0020-711x(90)90141-o.
1. Matrix-induced alkaline phosphatase prepared from rat osseous plate was solubilized with Polidocanol and purified on a Sephacryl S-300 column. 2. Purified solubilized alkaline phosphatase has a molecular weight of ca 115,000 and bind one magnesium and two zinc ions. At least 110 detergent molecules are bound to each enzyme molecule. 3. Solubilization and purification procedures did not destroy the ability of the enzyme to hydrolyze adenosine-5'-triphosphate, p-nitrophenylphosphate, pyrophosphate and bis p-nitrophenylphosphate. 4. Magnesium, manganese and cobalt ions are stimulators of PNPPase activity of solubilized enzyme whereas calcium and zinc ions are inhibitors.
Recent development of balloon-occluded retrograde transvenous obliteration
J Gastroenterol Hepatol 2019 Mar;34(3):495-500.PMID:30170340DOI:10.1111/jgh.14463.
Gastric varices (GVs) are a major complication of portal hypertension in patients with liver cirrhosis. The mortality rate associated with the bleeding from GVs is not low. Balloon-occluded retrograde transvenous obliteration (BRTO) was first introduced by Kanagawa et al. as a treatment for isolated GVs in 1994. It has been performed most frequently in Asia, especially in Japan. Ethanolamine oleate was the original sclerosant used in the therapy. Since the late 2000s, BRTO using sodium tetradecyl sulfate foam or Polidocanol foam as a sclerosant has been performed in many countries other than Japan. Then, early in the 2010s, modified BRTO techniques including vascular plug-assisted retrograde transvenous obliteration and coil-assisted retrograde transvenous obliteration were developed as an alternative treatment for GVs. This article provides a historical overview of BRTO using various sclerosants and modified BRTO techniques, such as plug-assisted retrograde transvenous obliteration and coil-assisted retrograde transvenous obliteration.